A phase I trial of the selective oral cyclin-dependent kinase inhibitor seliciclib (CYC202;R-Roscovitine), administered twice daily for 7-days every 21 days.

View/ Open
Author
Benson, C
White, J
De Bono, JS
O'Donnell, A
Raynaud, F
Cruickshank, C
McGrath, H
Frenz, L
Rose, F
Walton, M
Workman, P
Kaye, S
Type
Journal Article
Metadata
Show full item recordCollections
Research team
Clinical Pharmacology & Trials (including Drug Metabolism & Pharmacokinetics Group)
Medicine Drug Development Unit (Kaye)
Language
eng
Date accepted
2006-11-07
License start date
2006-11-07
Citation
Br J Cancer. 2007, Jan 15, 1 (96), pp. 29 - 37